Pregnancy. If a woman has been confirmed as pregnant she will not be eligible to take part in the trial. If she suspects there is a chance that she may be pregnant, a pregnancy test should be undertaken; however, a pregnancy test for all women of child-bearing potential is not mandatory
Negative serum pregnancy test in women of child-bearing potential within  days of day  (D) of treatment
Refusal to take a pregnancy test prior to treatment if the patient is a woman with child bearing potential
Women of child bearing potential must have a negative serum pregnancy test result within  days prior to initiation of study drug
Negative pregnancy test for women of child bearing potential
Negative serum pregnancy test and using medically acceptable form of contraception if of child bearing potential
Negative serum or urine pregnancy test within  days prior to the first dose of ALRN- for women of child-bearing potential
Negative pregnancy test in women of child bearing potential
Negative urine or serum pregnancy test performed =<  days prior to registration, for women of child bearing potential only
Negative pregnancy test in women of child-bearing potential
Negative pregnancy test for women of child bearing potential
Pregnant women are excluded from this study; breastfeeding women are also excluded; female subjects of child bearing potential must have a negative serum pregnancy test obtained prior to trial registration
Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy test within  days prior to randomization.
Women of child-bearing potential has negative pregnancy test prior to initiating study drug dosing
Women of child-bearing potential must have a negative pregnancy test
Women of child-bearing potential must have a negative pregnancy test
Women of child-bearing potential must have a negative pregnancy test
Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus.
Women of child-bearing potential must have a negative pregnancy test
Negative serum or urine pregnancy test for women with child-bearing potential
Pregnancy (positive pregnancy test) or lactation. Use of effective means of contraception (men and women) in subjects of child-bearing potential
Women of child-bearing potential (WOCBP) must have a negative pregnancy test within  days before study enrollment
Women of child bearing potential must have a negative serum pregnancy test, not be nursing, and use acceptable contraception
Subjects who are pregnant or planning to become pregnant during the study; women of child bearing potential must have a negative pregnancy test
A negative pregnancy test will be required for all women of child bearing potential; breast feeding is not permitted
Women of child-bearing potential must have a negative pregnancy test within  week of IORT treatment
CHEMOTHERAPY/CELL INFUSION ELIGIBILITY: For women of child-bearing potential, a negative serum pregnancy testing will be verified within  days prior to treatment
Pregnant or lactating women; women of child-bearing potential (WOCBP) must have a negative serum pregnancy test documented within  days prior to start of study drug
Women of child-bearing potential must have a negative pregnancy test; women of child-bearing potential are defined as all women who are not post-menopausal or who have not had a hysterectomy; postmenopausal will be defined as women over the age of  who have not had a menstrual period in at least  year
Women of child-bearing potential must have a negative pregnancy test
Women of child-bearing potential without a serum negative pregnancy test and not willing to refrain from sexual activity or to utilize an adeguate contraceptive methods during all the course of the study
Negative pregnancy test for women of child bearing potential
Women of child-bearing potential has negative pregnancy test within  hours of initiating study drug dosing
Women of child-bearing potential must have a negative pregnancy test  or fewer days from registration
Negative pregnancy test in women of child-bearing potential
(For both cohorts A and B): Women of child-hearing potential (WCBP) must have a negative pregnancy test within  days prior to the first dose of study treatment
Negative serum pregnancy test within  days of day  (D) of treatment in women of child bearing potential
Pregnant or breastfeeding; women of child bearing potential must have a negative pregnancy test at screening
Pregnant or breastfeeding - women of child bearing potential must have a negative pregnancy test at screening
Women who are pregnant or breast feeding; a pregnancy test will be administered to women of child bearing potential (per institutional policies) at screening; women must agree to pregnancy tests prior to (up to  calendar day) each administration of a radionuclidic agent, including tracer doses, to be considered for this study
Obtained =<  days prior to registration: Negative pregnancy test for persons of child-bearing potential
Negative pregnancy test for women of child-bearing potential within  hours prior to first dose of BMX-.
Women of child-bearing potential must have a negative serum or urine pregnancy test.
Women of child bearing potential must have a negative urine or blood pregnancy test within  days of study enrollment
Women must not be pregnant or breast-feeding\r\n* All female patients of child-bearing potential must have a negative serum pregnancy test within  weeks prior to treatment to rule out pregnancy \r\n* Pregnancy testing is not required for post-menopausal or surgically sterilized women
Women of child bearing potential: positive pregnancy test (serum)
Women of child-bearing potential must have a negative pregnancy test
Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus
Women of child bearing potential must have a negative pregnancy test; women of child-bearing potential are defined as all women except women who are post-menopausal or who have had a hysterectomy; postmenopausal will be defined as women over the age of  who have not had a menstrual period in at least  year
Women of child-bearing potential must have a negative pregnancy test
Women of child-bearing potential (WOCBP) must have a negative pregnancy test
Women of child-bearing potential must have a negative urinary or serum pregnancy test
Negative pregnancy test for women with child-bearing potential
Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to administration of each dose of JTX-
Negative pregnancy test for women of child bearing potential
Women of child bearing potential must have a negative pregnancy test by urinalysis
Women of child?bearing potential (e.g. not post?menopausal or permanently sterilized women) must have a negative pregnancy test obtained within  days prior to registration; this is to prevent potential harm to the fetus by glyburide and radiotherapy
Women of child-bearing potential must have negative pregnancy test prior to initiating study drug treatment
Women of child-bearing potential must have a negative pregnancy test
Pregnant or lactating  women of child bearing potential must have a negative pregnancy test within  days of study treatment start
Women of child-bearing potential (WOCBP) must have a negative pregnancy test within  days of registration; urine human gonadotropin (HCG) is an acceptable pregnancy assessment
Women of child-bearing potential must have a negative serum pregnancy test =<  hours prior to initiating treatment
Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating.
Women of child-bearing potential must have a negative pregnancy test at screening
Women of child-bearing potential must have a negative pregnancy test
For women of child-bearing potential, negative pregnancy test within  days prior to starting treatment
Pregnancy (positive pregnancy test) or lactation; use of effective means of contraception (men and women) in subjects of child-bearing potential
Women of child-bearing potential must have a negative pregnancy test
Women of child bearing potential only: Negative urine or serum pregnancy test
Women of child-bearing potential must have a negative pregnancy test
Pregnant or breast-feeding; urine pregnancy test will be assessed at the baseline visit in women of child-bearing potential with chronic pain
Negative pregnancy test for women of child-bearing potential
For women of child-bearing potential, negative serum pregnancy test within  days prior to registration
Subjects of child bearing potential must have a negative urine pregnancy test within  days prior to first dose of the study drug
Current or planned pregnancy or lactation in women of child bearing age (confirmed by negative pregnancy test prior to start of therapy)
Patients must not be pregnant; women of child-bearing potential must also have a negative pregnancy test within  weeks prior to start of protocol therapy (radiation and veliparib)
Negative pregnancy test (serum or urine) for women of child bearing potential; all protocol participants must agree to adequate contraception
Women of child-bearing potential must have a negative pregnancy test
Breast-feeding or pregnant; serum pregnancy test for women of child-bearing potential must be performed within  days prior to first dose of study treatment
Negative serum pregnancy test for women of child-bearing potential
Negative pregnancy test for women of child-bearing age
Women of child bearing age must be using adequate birth control and have a negative pregnancy test
Women of child-bearing age must be using adequate birth control and have a negative pregnancy test
Pregnant women are excluded; therefore negative pregnancy test is required for all women of child-bearing age, and appropriate contraception is used during the study period
Patients who are pregnant; negative pregnancy test is required for all women of child-bearing age, and appropriate contraception is required during the study period
Child bearing age women with positive pregnancy test
Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus
Pregnant or breastfeeding - The agents used in this study include those that fall under Pregnancy Category D - have known teratogenic potential. Women of child bearing potential must have a negative pregnancy test at screening
Women of child-bearing potential must have a negative serum pregnancy test within  days prior to first dose of abemaciclib
Negative pregnancy test in women of child bearing potential
Negative serum pregnancy test result in women of child-bearing potential (WOCBP)
Negative pregnancy test for women with child-bearing potential
Negative pregnancy test for women of child bearing potential
All women of child-bearing potential who take ribavirin will need to have a negative pregnancy test
Women of child-bearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least  mIU/mL within  days and again within  hours prior to beginning study treatment
Women of child bearing potential must have a negative pregnancy test
Pregnant or lactating  women of child bearing potential must have a negative pregnancy test within  days of study treatment start
Women of child-bearing potential must have a negative pregnancy test
For women of child bearing potential, a negative serum pregnancy testing will be verified within  days prior to pre chemotherapy apheresis
Women must: have a negative serum or urine pregnancy test within  days prior to study entry if she is a woman of child-bearing potential (WOCBP), or be at least one year post-menopausal, OR be surgically sterile
Negative pregnancy test (serum or urine) within  days of registration in women of child-bearing potential
Negative pregnancy test for women of child bearing potential
Women of child-bearing potential must have a negative serum pregnancy test within  days prior to randomization
In women of child-bearing potential, negative serum pregnancy test within  days of the first infusion of G-
Woman of child-bearing potential has negative pregnancy test before the initiation of study drug dosing
Women of child bearing potential must have a negative serum pregnancy test.
For women of child-bearing potential, a negative urine pregnancy test
Women of child bearing potential must not be pregnant; a pre-study pregnancy test must be negative
Pregnant and nursing women are excluded; men and women of child-bearing potential are eligible but must consent to using effective contraception during therapy and for at least  months after completing therapy; women with child-bearing potential must have a negative serum or urine beta-human chorionic gonadotropin (B-hCG) pregnancy test at screening
A negative pregnancy test will be required for all women of child bearing potential; breast feeding is not permitted
Negative serum pregnancy test for women of child-bearing potential
Patients with child-bearing potential must have a negative urine pregnancy test within  days prior to registration
A negative serum pregnancy test obtained within  weeks prior to the start of treatment in all women of child-bearing potential
Women of child-bearing potential must have a negative (urine or blood) pregnancy test within  weeks prior to start of protocol therapy; women of child-bearing potential must also use effective non-hormonal contraception while undergoing radiation therapy
Negative pregnancy test for women with child-bearing potential
Patients must not be pregnant (positive pregnancy test) or breast feeding; pregnancy test must be done within  days prior to registration; effective contraception (men and women) must be used in patients of child-bearing potential while on study treatment and for  months after
Patient refuses to take a pregnancy test prior to treatment if the patient is a woman with child bearing potential
In women of child-bearing potential, negative serum pregnancy test within  hours prior to day  of study treatment and agree to use effective contraception
Pregnant or lactating women; women of childbearing potential must have a negative pregnancy test at screening; women of child bearing potential must undergo pregnancy testing prior to each dose if the previous pregnancy test was greater than  days prior and a pregnancy test at  months after the last dose
Women of child bearing potential must undergo pregnancy testing within  days of the first dose of study therapy; women must also undergo pregnancy test at  months after the last dose
Woman of child-bearing potential has negative pregnancy test before the initiation of study drug dosing
Negative urine pregnancy test within one week before starting treatment in women of child-bearing potential
Women must:\r\n* Have a negative serum or urine pregnancy test within  days prior to study entry if she is a woman of child-bearing potential, OR\r\n* Be at least one year post-menopausal, OR\r\n* Be surgically sterile
Negative pregnancy test in women of child-bearing potential
Pregnancy (positive pregnancy test) or lactation- breast feeding; lack of effective means of contraception (men and women) in subjects of child-bearing potential
Pregnancy (positive pregnancy test) or lactation; (an effective means of contraception [men and women] in subjects of child-bearing potential must be used)
Women of child-bearing potential must have a negative pregnancy test
Pregnant or breastfeeding; women of child bearing potential must have a negative pregnancy test within  days of study treatment start
Negative urine or serum pregnancy test done =<  days prior to randomization, for women of child bearing potential only
Women of child bearing potential must have a negative pregnancy test
Pregnancy in women of child bearing potential (pregnancy test performed within  weeks of study entry)
Women of child bearing potential having a positive urine or serum pregnancy test (hCG) at the time of pre-operative evaluation (within  days of surgery)
Pregnant women are excluded for fear of danger to the fetus; therefore negative pregnancy test is required for all women of child-bearing age, and appropriate contraception is required during the study period
Women of child-bearing potential must have a negative pregnancy test
Subjects who are women of child-bearing potential must not be pregnant or lactating, must have a negative pregnancy test at Day .
Negative serum pregnancy test for women of child-bearing potential
Negative pregnancy test for women of child-bearing potential.
Women of child bearing potential must have a negative pregnancy test and use reliable methods of contraception
Patients with child bearing potential must have a negative pregnancy test (urine or serum) prior to study treatment
Women of child-bearing potential must have a negative pregnancy test
Women of child-bearing potential must have a negative pregnancy test
Women of child-bearing potential will be required to undergo a negative pregnancy test prior to enrollment, and women who are currently pregnant will not be considered eligible
Women of child-bearing age must have a negative, quantitative serum pregnancy test =<  days prior to study entry, or have a documented reason why such a test is not necessary (e.g. history of tubal ligation)
Women of child-bearing age must have a negative pregnancy test
Women of child bearing potential must have a negative serum pregnancy test
For women of child-bearing potential, negative pregnancy test within  days prior to starting treatment
Pregnant or lactating women. Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test documented within  hours prior to starting study drug or a urine pregnancy test shall be done on Day  of Cycle 
Women of child bearing potential must have a negative pregnancy test
Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy test within  days prior to randomization.
Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating.
Positive pregnancy test in women of child-bearing potential.
Serum pregnancy test for women of child bearing potential must be negative at entry into study
Women of child-bearing potential must have a negative pregnancy test within  days prior to commencement of study treatment
Women of child-bearing potential must have a negative pregnancy test
Women of child-bearing potential must have a negative pregnancy test
Women of child-bearing potential must have a negative pregnancy test.
Negative pregnancy test (urinary or serum beta-HCG) at screening (applicable to women of child bearing potential who are sexually active)
Women of child bearing potential must not be pregnant; a pre-study pregnancy test must be negative
Women of child-bearing potential must have a negative pregnancy test within  days prior to the first dose of study treatment.
Women of child-bearing potential must have a negative pregnancy test
Women of child-bearing potential must have a negative pregnancy test
For women of child-bearing potential, negative serum pregnancy test within  days prior to registration
Women of child-bearing potential must have a negative pregnancy test prior to initiating study treatment
Women of child bearing potential between the ages of  and  years of age must have a negative urine pregnancy test prior to undergoing simulation in preparation for radiation therapy to the pelvis
Pregnancy (positive pregnancy test) or lactation; use of effective means of contraception (men and women) in subjects of child-bearing potential
Women of child bearing potential with a negative urine or blood pregnancy test within a month of enrollment (only for patients who are going to be randomized to either therapeutic arms)
Women of child-bearing age must have a negative, quantitative serum pregnancy test =<  days prior to study entry, or have a documented reason why such a test is not necessary (e.g. history of tubal ligation)
Pregnant or nursing women - women of child?bearing potential must have negative serum or urine pregnancy test
Pregnancy or lactation; negative pregnancy test is required within the screening window for women of child bearing potential
Women of child-bearing potential must have a confirmed negative pregnancy test result prior to enrollment
Pregnant or breastfeeding; women of child bearing potential must have a negative pregnancy test at screening
Negative urine pregnancy test within  weeks of registration for women of child-bearing potential; women of child-bearing potential must have a documented negative pregnancy test and agree to use adequate contraception throughout the study period
Women of child-bearing potential must have a negative pregnancy test within one week of IORT treatment
Negative serum pregnancy test, if of child-bearing potential
Negative serum pregnancy test for women of child bearing potential (WOCBP)
Women of child-bearing potential must have a negative urinary or serum pregnancy test within  days of baseline imaging
Women of child bearing potential must have a negative serum pregnancy test
PATIENT: If of child-bearing potential, must have a negative pregnancy test
Women of child bearing potential with negative pregnancy test documented
Negative pregnancy test for women of child-bearing potential
Negative urine pregnancy test in women of child-bearing potential
Women of child-bearing potential must have a negative blood pregnancy test at screening and use an adequate and medically acceptable contraceptive method.
Negative serum pregnancy test for women of child bearing potential
Women of child bearing potential must have a negative serum pregnancy test no more than  hours prior to registration
Negative urine pregnancy test in women of child-bearing potential (WCBP) within  week prior to s-DCT
Negative pregnancy test if of child-bearing age
Women of child-bearing age will be asked to undergo a pregnancy test prior to enrollment
Patients who are pregnant or breast feeding; urine pregnancy test will be performed on women of child bearing potential
Patients of child-bearing potential must have a negative urine or serum pregnancy test
Women who are not of child-bearing potential, and women of child-bearing potential who agree to use adequate contraceptive measures during the study and for  days after the last dose of study medication, and who have a negative serum or urine pregnancy test within  week prior to initial trial treatment.
